<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369543">
  <stage>Registered</stage>
  <submitdate>30/10/2015</submitdate>
  <approvaldate>5/11/2015</approvaldate>
  <actrnumber>ACTRN12615001201561</actrnumber>
  <trial_identification>
    <studytitle>A randomized, placebo-controlled study of the safety and tolerability of PTG-100 in healthy volunteers</studytitle>
    <scientifictitle>A randomized, double-blind, placebo-controlled study of single and multiple ascending doses of PTG-100 in normal healthy volunteers.</scientifictitle>
    <utrn>U1111-1175-9986 </utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>gastrointestinal</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral administration
Starting dose 100mg, then 300mg and 1000mg.
Single (=1 day) and multiple (=14 days) for each dose of PTG-100
Each dose tested in a new cohort</interventions>
    <comparator>placebo consists of buffer/excipient without any active drug</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability will be assessed using vital signs, clinical safety labs, ECGs, physical exams and adverse events.</outcome>
      <timepoint>daily in-patient monitoring for 2 days following first dose in single dose part of the study and daily plus two days after last dose in multiple dose part.
Subjects return for end of study visit 7 days after last dose. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>PK sample parameters include Cmax, Tmax and AUC calculated from blood plasma samples. </outcome>
      <timepoint>PK samples will be collected at the following time points:
0, 15 mins, 30 mins, and hours 1, 2, 4, 8, 12, 24, 36, and 48 after the dose in the single dose part and also at the same time points in the multiple dose part on days 1, 11 and 14.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Normal healthy volunteers 18-55 years
Good general health
BMI 18-30kg/m2
Lab values within normal range
Ability and willingness to attend visits to the site</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>History of significant abnormalities or diseases
Clinical significant lab or ECG abnormalities
Mentally or legally incapacitated
History of substance abuse
Inability to comply with the requirements of the study protocol </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>21/12/2015</anticipatedstartdate>
    <actualstartdate>17/12/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate>23/05/2016</actualenddate>
    <samplesize>70</samplesize>
    <actualsamplesize>78</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>18/07/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Protagonist Therapeutics Pty Ltd</primarysponsorname>
    <primarysponsoraddress>306 Carmody Road
St Lucia
Brisbane
4067
QLD</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Protagonist Therapeutics</fundingname>
      <fundingaddress>306 Carmody Road
St Lucia
Brisbane
4067
QLD</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>CNS Pty Ltd</sponsorname>
      <sponsoraddress>88 Jephson Street
Toowong
QLD 4066</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is to assess the safety and tolerability of PTG-100 to normal healthy volunteers.
This includes vital signs, safety labs and physical examinations

The drug will be given in single ascending then multiple ascending doses.

The study will also evaluate the PK of the drug after dose administration.
Participants will be entered into standard study cohorts</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Office of Ethics and Research Governance </ethicname>
      <ethicaddress>The Alfred Hospital
55 Commercial Rd
Melbourne
VIC 3004</ethicaddress>
      <ethicapprovaldate>2/12/2015</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>26/10/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jason Lickliter</name>
      <address>Nucleus Network Ltd
 5th Floor, Burnet Tower, AMREP Precinct
 89 Commercial Road
 Melbourne, Victoria, 3004</address>
      <phone>+61 3 9076 8960</phone>
      <fax />
      <email>J.Lickliter@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Lucio Tozzi</name>
      <address>521 Cottonwood Drive, Ste 100
Milpitas, CA 95035</address>
      <phone>+1 408 649 7370</phone>
      <fax />
      <email>l.tozzi@protagonist-inc.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Lucio Tozzi</name>
      <address>521 Cottonwood Drive, Ste 100
Milpitas, CA 95035</address>
      <phone>+1 408 649 7370</phone>
      <fax />
      <email>l.tozzi@protagonist-inc.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Lucio Tozzi</name>
      <address>521 Cottonwood Drive, Ste 100
Milpitas, CA 95035</address>
      <phone>+1 408 649 7370</phone>
      <fax />
      <email>l.tozzi@protagonist-inc.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>